Evelo Biosciences, Inc. (EVLO)
| Market Cap | 1.90K -99.8% |
| Revenue (ttm) | n/a |
| Net Income | -82.35M |
| EPS | -9.65 |
| Shares Out | 18.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133 |
| Average Volume | 2,444 |
| Open | 0.0005 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0005 |
| 52-Week Range | 0.000001 - 0.0020 |
| Beta | 1.67 |
| RSI | 46.92 |
| Earnings Date | Mar 30, 2026 |
About Evelo Biosciences
Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of i... [Read more]
News
Evelo Biosciences Shareholders Approve Dissolution Plan
Evelo Biosciences Inc (EVLO) has released an update to notify the public and investors about the submission of matters to a vote of security holders. On January 26, 2024, Evelo…
Evelo Biosciences cut to Market Perform at TD Cowen after phase 2 EDP2939 data
TD Cowen downgraded Evelo Biosciences to Market Perform from Outperform. The firm is citing the company’s announcement earlier today that it will explore strategic alternatives and partnering opportun...
Evelo Biosciences downgraded to Market Perform from Outperform at TD Cowen
TD Cowen analyst Joseph Thome downgraded Evelo Biosciences to Market Perform from Outperform without a price target.
Horizon Technology downgraded to Sell from Neutral at Compass Point
Compass Point downgraded Horizon Technology (HRZN) to Sell from Neutral with a $10 price target after Evelo Biosciences (EVLO) announced its Phase 2 clinical study with EDP2939 in moderate psoriasis…
Evelo Biosciences to review options after Phase 2 trial of psoriasis treatment fails to meet main goal
Evelo Biosciences Inc. EVLO, -6.73% said Tuesday it's reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal. “The s...
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Primary endpoint was not achieved – - Company exploring strategic alternatives and partnering opportunities for EDP1815 and its SINTAX platform - CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Evelo Biosciences (EVLO), 54% surge in interest Catalyst ...
Evelo Biosciences trading halted, volatility trading pause
09:34 EDT Evelo Biosciences trading halted, volatility trading pause
Evelo Biosciences reports Q2 EPS ($3.78) vs ($8.07)
Simba Gill, Ph.D., Evelo’s Chief Executive Officer, said, “We are on track for a top line read-out from our ongoing Phase 2 study in moderate psoriasis with EDP2939, our first…
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023 – Completed $25.5 Million Private Placement – Restructured and reduced secured debt with Horizon T...
Evelo Biosciences files to sell 13.19M shares of common stock for holders
16:06 EDT Evelo Biosciences files to sell 13.19M shares of common stock for holders
Horizon Technology price target raised to $11.75 from $11.25 at Compass Point
Compass Point analyst Casey Alexander raised the firm’s price target on Horizon Technology (HRZN) to $11.75 from $11.25 and keeps a Neutral rating on the shares. Evelo Biosciences (EVLO) used…
Moderna Co-Founder Bought Up This Embattled Biotech Stock
Flagship Pioneering, an investment vehicle helmed by Noubar Afeyan, a co-founder of Moderna and its chairman, bought $12.5 million of shares of biotech Evelo.
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduce s secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving...
Evelo Biosciences Announces Reverse Stock Split Effective
– EVLO common stock expected to begin trading on a split-adjusted basis on June 30, 2023 – CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage b...
Evelo Biosciences Provides Clinical Updates
– Topline Data from fourth cohort of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint – – Company will focus on development of extracellular vesicles (EVs) – – First EV candida...
Evelo Biosciences Earnings Call Transcript: Q4 2022
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally del...
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolvi...
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory med...
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –
Evelo Biosciences Provides Clinical and Business Updates
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed – – Clear path to registration trials for EDP...